(MedPageToday) Infliximab and abatacept showed trends for improved outcomes in ACTIV-1 IM trial. Use of the anti-inflammatory agents infliximab (Remicade) and abatacept (Orencia) added to standard of care showed a hint of improvement in outcomes for patients hospitalized with COVID-19 pneumonia, according to results from the ACTIV-1 IM trial. Compared with a median time to recovery of 9 days with placebo, it was 8 days with infliximab (OR 1.13, 95% CI 0.99-1.29, P=0.063) and 9 days with abatacept (OR 1.14, 95% CI 1.00-1.29, P=0.057), reported Emily Ko, MD, PhD, of Duke University Health System in Durham, North Carolina, during her late-breaking presentation at IDWeek.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.